Hanmi Pharmaceutical reported record-breaking sales of approximately $1.16 billion for January 2025, a 3.5% increase from the same period last year, according to a disclosure on Thursday.
The company’s operating profit climbed 19.2% year over year to about $193.35 million, while net profit surged 33.9% to about $141.08 million. These figures represent all-time highs for the pharmaceutical giant.
In the external prescription sector, Hanmi Pharmaceutical generated approximately $812.7 million in sales last year. Their combination dyslipidemia drug, Rosuzet, saw an 8.4% increase in sales, reaching approximately $170.93 million. The Amozartan Family, a line of hypertension treatments, brought in about $109.05 million in sales.
Beijing Hanmi Pharmaceutical, the company’s Chinese subsidiary, posted impressive results with sales of approximately $301.8 million, operating profit of around $58.28 million, and net profit of about $50.55 million. These gains were attributed to inventory clearance in China and increased demand for respiratory medications like Ianping and Yitanjing.
Hanmi Precision Chemical, the company’s API specialist subsidiary, achieved sales of approximately $68.48 million. Fourth-quarter sales jumped 36.8% year-over-year to around $21.23 million. The subsidiary reported a turnaround to profitability in Q4, crediting new CDMO contracts and expanded volumes from existing projects.
Looking ahead, Hanmi Pharmaceutical expects to enter a high-growth phase this year. Following the recent launch of Amoprel, a low-dose antihypertensive drug, the company aims to introduce at least one flagship product annually, each projected to generate over approximately $7.5 million in yearly sales.
On the R&D front, Hanmi plans to unveil clinical results from its key pipelines in oncology, obesity and metabolism, and rare diseases at major global conferences throughout the year.
The company highlighted tangible progress in its obesity drug project, H.O.P (Hanmi Obesity Pipeline), with Efpegerglucagon slated for market release in the latter half of this year.
Hanmi is also advancing its next-generation obesity treatments, including a triple-action drug (LA-GLP/GIP/GCG, HM15275) targeted for 2030 commercialization, and the world’s first muscle-enhancing obesity treatment (LA-UCN2, HM17321) aimed for a 2031 launch.
CEO Park Jae Hyun of Hanmi Pharmaceutical said that the company remains committed to leveraging its corporate strengths to deliver sustainable results and enhance shareholder value, with the goal of repaying the trust and support of all its stakeholders.